Whittier Trust Co. cut its stake in Novartis AG (NYSE:NVS) by 2.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,960 shares of the company’s stock after selling 1,832 shares during the quarter. Whittier Trust Co.’s holdings in Novartis were worth $5,317,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. AlphaMark Advisors LLC acquired a new stake in shares of Novartis in the 4th quarter valued at approximately $30,000. Sonora Investment Management LLC increased its position in shares of Novartis by 93.9% in the fourth quarter. Sonora Investment Management LLC now owns 479 shares of the company’s stock worth $41,000 after purchasing an additional 232 shares during the last quarter. Cornerstone Advisors Inc. increased its position in shares of Novartis by 89.4% in the third quarter. Cornerstone Advisors Inc. now owns 502 shares of the company’s stock worth $43,000 after purchasing an additional 237 shares during the last quarter. Lavaca Capital LLC bought a new position in Novartis during the fourth quarter valued at approximately $48,000. Finally, Focused Wealth Management Inc grew its position in Novartis by 29.9% during the fourth quarter. Focused Wealth Management Inc now owns 868 shares of the company’s stock valued at $74,000 after acquiring an additional 200 shares during the last quarter. 10.99% of the stock is currently owned by institutional investors.

NVS stock traded up $0.86 during mid-day trading on Monday, reaching $89.88. 2,351,443 shares of the company’s stock were exchanged, compared to its average volume of 2,114,598. The company has a market capitalization of $207.62 billion, a P/E ratio of 17.66, a P/E/G ratio of 1.93 and a beta of 0.69. The company has a current ratio of 1.20, a quick ratio of 0.97 and a debt-to-equity ratio of 0.29. Novartis AG has a 12-month low of $72.30 and a 12-month high of $92.39.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Wednesday, January 30th. The company reported $1.24 EPS for the quarter, missing the Zacks’ consensus estimate of $1.33 by ($0.09). The company had revenue of $13.27 billion for the quarter, compared to analysts’ expectations of $13.33 billion. Novartis had a return on equity of 15.66% and a net margin of 24.30%. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.21 EPS. On average, research analysts predict that Novartis AG will post 5.43 earnings per share for the current fiscal year.

The company also recently disclosed an annual dividend, which will be paid on Wednesday, March 13th. Stockholders of record on Tuesday, March 5th will be paid a $2.8646 dividend. The ex-dividend date of this dividend is Monday, March 4th. This is a boost from Novartis’s previous annual dividend of $2.33. This represents a dividend yield of 3.27%. Novartis’s payout ratio is presently 37.52%.

A number of analysts recently commented on the company. JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Novartis in a research note on Wednesday, January 16th. Credit Suisse Group downgraded Novartis to a “sell” rating in a report on Thursday, December 20th. Wolfe Research began coverage on Novartis in a report on Tuesday, October 23rd. They issued an “outperform” rating for the company. Goldman Sachs Group raised Novartis from a “neutral” rating to a “conviction-buy” rating in a research report on Friday, November 16th. Finally, Cowen raised Novartis from a “market perform” rating to an “outperform” rating and set a $100.00 price objective on the stock in a research report on Monday, November 26th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Novartis has an average rating of “Hold” and an average price target of $90.94.

WARNING: This piece was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://theolympiareport.com/2019/02/18/novartis-ag-nvs-shares-sold-by-whittier-trust-co.html.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Featured Story: What are the components of an earnings report?

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.